Financial Performance - The company reported a net loss of $99.0 million for the three months ended March 31, 2025, compared to a net loss of $49.8 million for the same period in 2024, resulting in an accumulated deficit of $757.5 million as of March 31, 2025[215]. - Total revenue for the three months ended March 31, 2025, was $17.4 million, all from license revenue, compared to no revenue in the same period in 2024[251][252]. - The net loss for the three months ended March 31, 2025, was $99.0 million, a 99% increase from a net loss of $49.8 million in the same period in 2024[251]. - The net cash used in operating activities for the three months ended March 31, 2025, was $80.4 million, compared to $44.3 million for the same period in 2024, indicating a significant increase in operational losses[276][278]. - The company reported a net loss of $99.0 million for the three months ended March 31, 2025, which was partially offset by changes in operating assets and liabilities of $11.5 million and non-cash items totaling $7.1 million[277]. Research and Development - The company is developing two TYK2 inhibitors: ESK-001, which is in Phase 3 trials for plaque psoriasis, and A-005, which is in Phase 1 trials for CNS indications[212]. - The company has incurred significant operating losses primarily due to research and development costs, with fluctuations expected based on the timing of clinical trials and product candidate acquisitions[216]. - Research and development expenses increased by 130% to $96.6 million for the three months ended March 31, 2025, from $41.9 million in the same period in 2024[251][253]. - External research and development costs for ESK-001 were $66.5 million for the three months ended March 31, 2025, up from $24.7 million in the same period in 2024[260]. - Personnel-related costs in research and development increased by 94% to $17.7 million for the three months ended March 31, 2025, from $9.1 million in the same period in 2024[253][258]. - The company incurred a milestone payment of $23.0 million in August 2024 related to the first administration of ESK-001 in a Phase 3 clinical trial, recorded in research and development expenses[285]. Collaboration and Partnerships - The company has entered into a Collaboration Agreement with Kaken for the development and commercialization of ESK-001 in Japan, retaining rights for all other indications and geographies[232]. - Kaken made a non-refundable upfront payment of $20.0 million and will pay an additional $20.0 million towards global development costs of ESK-001 through the end of 2026[236]. Funding and Capital Requirements - The company anticipates significant increases in expenses related to ongoing clinical trials, potential mergers, and the establishment of commercialization capabilities[218]. - The company anticipates needing substantial additional funding to support ongoing research and development activities and maintain future operations[269]. - As of March 31, 2025, the company has cash, cash equivalents, and marketable securities totaling $208.7 million, which is insufficient to meet operating and capital requirements for at least the next 12 months[268]. - The company reported net cash provided by financing activities of $129.1 million for the three months ended March 31, 2024, primarily from the issuance of Series C redeemable convertible preferred stock[283]. Market and Economic Conditions - The company is subject to macroeconomic trends that could impact its operations, including rising inflation, interest rates, and geopolitical instability, although these have not yet materially affected its business[225]. - Inflation has not had a material effect on the company's business or financial condition[310]. - The company does not believe that a hypothetical 10% increase or decrease in interest rates would have a material effect on its financial statements[308]. Accounting and Financial Reporting - The company recognizes revenue based on the transfer of control over promised goods or services, either at a point in time or over time, with adjustments recorded on a cumulative catch-up basis[295]. - Accounts receivable are recorded when the right to consideration is deemed unconditional, while consideration that does not meet revenue recognition criteria is classified as deferred revenue[296]. - Stock-based compensation expense is measured using the Black-Scholes option-pricing model, with assumptions including common stock fair value and expected volatility, and is expensed over the requisite service period[297]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay the adoption of certain accounting standards until they apply to private companies[303]. - As of June 30, 2024, the company qualifies as a "smaller reporting company," with a market value of common stock and non-voting common stock held by non-affiliates less than $700.0 million and annual revenue below $100.0 million[305]. Risks and Uncertainties - The company is subject to risks related to the development of new drug candidates, which may lead to unforeseen expenses and delays[269]. - Foreign currency transaction gains and losses have not been material, and the company does not have a formal hedging program for foreign currency[309].
Alumis Inc.(ALMS) - 2025 Q1 - Quarterly Report